alpha-aminopyridine has been researched along with Anti-MuSK Myasthenia Gravis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (90.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Desai, A; Gadgeel, SM; Lisak, RP; Sriwastava, S | 1 |
| Murray, NM; Newsom-Davis, J | 1 |
| Kam, P; Soni, N | 1 |
| Riggs, JE | 1 |
| Lundh, H; Nilsson, O; Rosén, I | 4 |
| Heilbronn, E | 1 |
| Zhang, YP; Zheng, W | 1 |
4 review(s) available for alpha-aminopyridine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
4-aminopyridine-a review.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Botulism; Central Nervous System; Humans; Ion Channels; Myasthenia Gravis; Neuromuscular Blocking Agents; Neuromuscular Depolarizing Agents; Neuromuscular Diseases; Neuromuscular Junction; Structure-Activity Relationship | 1982 |
Pharmacologic enhancement of neuromuscular transmission in myasthenia gravis.
Topics: 4-Aminopyridine; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Ambenonium Chloride; Aminopyridines; Calcium; Cholinesterase Inhibitors; Cyclic AMP; Edrophonium; Ephedrine; Germine Acetates; Guanidine; Guanidines; Humans; Myasthenia Gravis; Neostigmine; Neuromuscular Depolarizing Agents; Neuromuscular Junction; Potassium; Pyridostigmine Bromide; Synapses; Synaptic Transmission | 1982 |
Short review of progress in experimental myasthenia gravis, bearing on the pathogenesis of myasthenia gravis.
Topics: Aminopyridines; Animals; Autoantibodies; Humans; Immunization, Passive; Motor Endplate; Myasthenia Gravis; Receptors, Cholinergic; Thymus Gland | 1979 |
[Research progress on a new potassium channel-blocking agent--4-aminopyridine].
Topics: 4-Aminopyridine; Amifampridine; Aminopyridines; Animals; Humans; Ion Channels; Myasthenia Gravis; Potassium | 1986 |
6 other study(ies) available for alpha-aminopyridine and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Myasthenia Gravis; Pyrazoles | 2018 |
Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.
Topics: Adult; Aminopyridines; Female; Humans; Infant; Male; Middle Aged; Muscles; Myasthenia Gravis; Neuromuscular Diseases; Neuromuscular Junction; Synaptic Transmission | 1981 |
Novel drug of choice in Eaton-Lambert syndrome.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Female; Humans; Middle Aged; Myasthenia Gravis; Neuromuscular Junction; Synaptic Transmission | 1983 |
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Autoimmune Diseases; Female; Humans; Middle Aged; Myasthenia Gravis; Pyridostigmine Bromide; Syndrome | 1984 |
Effects of 4-aminopyridine in myasthenia gravis.
Topics: Action Potentials; Adult; Aminopyridines; Female; Humans; Male; Middle Aged; Muscle Contraction; Myasthenia Gravis | 1979 |
Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Aged; Amifampridine; Aminopyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electromyography; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Junction; Pyridostigmine Bromide; Synaptic Transmission | 1985 |